IGM Biosciences Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Igm Biosciences, Inc. |
| Form Type | 10-Q |
| Filed Date | May 13, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
IGM Biosciences Q1 2025 10-Q filed. R&D and G&A expenses detailed. Medivir deal from 2021 mentioned.
AI Summary
IGM Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance, including research and development expenses and general and administrative expenses for the first quarter of 2025. It also references past events such as a license agreement with Medivir AB dated January 31, 2021.
Why It Matters
This filing provides investors with an update on IGM Biosciences' financial health and operational activities during the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — The company operates in the volatile pharmaceutical sector, with significant R&D expenses and potential for clinical trial outcomes to impact its valuation.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-01-01 — Quarter Start Date (Marks the beginning of the financial quarter for expense reporting.)
Key Players & Entities
- IGM Biosciences, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- Medivir AB (company) — Party to a license agreement
- January 31, 2021 (date) — Date of license agreement with Medivir AB
FAQ
What were the total research and development expenses for the first quarter of 2025?
The filing indicates research and development expenses for the period January 1, 2025 to March 31, 2025.
What were the general and administrative expenses for the first quarter of 2025?
General and administrative expenses for the period January 1, 2025 to March 31, 2025 are detailed in the filing.
Does the filing mention any significant collaborations or agreements?
Yes, the filing references a license agreement with Medivir AB dated January 31, 2021.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What is the company's primary industry classification?
The company is classified under Pharmaceutical Preparations [2834].
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding IGM Biosciences, Inc..